Compare Boston Scientific Corporation (BSX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Xylem, Inc. — how do they compare? Boston Scientific Corporation trades at $51.61 (market cap $74.19B), while Xylem, Inc. trades at $121.88 (market cap $28.76B). The key difference: Boston Scientific Corporation is far larger — about 2.6× Xylem, Inc.'s market cap, and Xylem, Inc. pays a 1.4% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | XYL | |
|---|---|---|
Market Cap | $74.19B | $28.76B |
Sector | Health | Industrials |
52-Week High | $108.14 | $152.95 |
52-Week Low | $42.63 | $106.34 |
Enterprise Value | $86.27B | $30.54B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
XYL trades at $121.59, up 0.33% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin expanding to 10.59%. Recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water technology presence, while AI-driven demand for water-treatment equipment supports growth.
The outlook is positive, with a consensus price target of $150.43 implying 24% upside, backed by margin expansion and strategic acquisitions. Risks include execution of integration and potential revenue delays from electric metering projects, as noted in Q2 2026 results. Analyst sentiment is mixed but leans bullish, with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
